---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-25-000241"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T22:47:57.846475+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.88
calibrated_materiality_score: 0.88
confidence: "high"
source: SEC EDGAR
---

# Dexcom Q2 revenue $1.157B (+15% YoY); raises FY25 revenue guidance; CEO Sayer to retire, Jake Leach named CEO

## Summary
- Revenue $1.157B (+15% YoY); GAAP EPS $0.45, non-GAAP EPS $0.48.
- Raises FY25 revenue guidance to $4.600-4.625B (14-15% growth); margins reiterated.
- CEO Kevin Sayer to retire Jan 1, 2026; becomes Executive Chairman. COO Jake Leach promoted to CEO and Board.
- FDA clearance for Dexcom G7 15 Day CGM System received in Q2.
- U.S. revenue +15%, international +16% reported (+14% organic).

## SEC filing metadata
- accession: 0001093557-25-000241
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.88
- calibrated_materiality_score: 0.88
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000241/0001093557-25-000241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000241/dxcm-20250725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-25-000241
- JSON: https://secwatch.observer/filing/0001093557-25-000241.json
- Plain text: https://secwatch.observer/filing/0001093557-25-000241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.